BSE Live
Sep 29, 16:01Prev. Close
875.80
Open Price
876.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 29, 15:49Prev. Close
869.30
Open Price
878.90
Bid Price (Qty.)
876.40 (4)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Cohance Lifesciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 1,068.31 | 1,009.49 | 1,320.86 | 1,307.01 | 995.46 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 1,068.31 | 1,009.49 | 1,320.86 | 1,307.01 | 995.46 | |
Total Operating Revenues | 1,093.51 | 1,024.99 | 1,330.08 | 1,320.22 | 1,009.72 | |
Other Income | 53.98 | 55.09 | 44.55 | 187.79 | 14.24 | |
Total Revenue | 1,147.49 | 1,080.09 | 1,374.63 | 1,508.01 | 1,023.96 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 212.51 | 248.38 | 421.36 | 459.46 | 310.32 | |
Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Operating And Direct Expenses | 0.00 | 127.78 | 170.87 | 173.19 | 122.73 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | 86.53 | 53.88 | -20.94 | -60.35 | -8.37 | |
Employee Benefit Expenses | 198.30 | 126.88 | 100.84 | 100.48 | 87.29 | |
Finance Costs | 8.00 | 7.43 | 5.39 | 6.23 | 9.14 | |
Depreciation And Amortisation Expenses | 57.20 | 48.79 | 42.84 | 39.10 | 31.64 | |
Other Expenses | 233.60 | 58.17 | 74.87 | 67.46 | 57.23 | |
Total Expenses | 796.14 | 671.31 | 795.24 | 785.56 | 609.98 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 351.35 | 408.77 | 579.39 | 722.45 | 413.98 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 351.35 | 408.77 | 579.39 | 722.45 | 413.98 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 85.80 | 98.14 | 144.63 | 157.63 | 101.54 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -12.73 | 6.59 | 4.34 | 6.72 | 3.62 | |
Tax For Earlier Years | 6.57 | -0.78 | -2.17 | 0.00 | 0.18 | |
Total Tax Expenses | 79.64 | 103.96 | 146.79 | 164.35 | 105.33 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 271.71 | 304.82 | 432.60 | 558.10 | 308.65 | |
Profit/Loss From Continuing Operations | 271.71 | 304.82 | 432.60 | 558.10 | 308.65 | |
Profit/Loss For The Period | 271.71 | 304.82 | 432.60 | 558.10 | 308.65 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 10.67 | 11.97 | 16.99 | 21.92 | 12.12 | |
Diluted EPS (Rs.) | 10.62 | 11.97 | 16.99 | 21.92 | 12.12 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 0.00 | 0.00 | 203.65 | 101.83 | 25.46 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 0.00 | 0.00 | 600.00 | 500.00 | 200.00 |
12.06.2025
Cohance Life Standalone March 2025 Net Sales at Rs 330.17 crore, up 35.58% Y-o-Y
04.03.2025
Suven Pharma Consolidated December 2024 Net Sales at Rs 307.15 crore, up 39.73% Y-o-Y
28.11.2024
Suven Pharma Consolidated September 2024 Net Sales at Rs 257.72 crore, up 11.54% Y-o-Y
14.11.2024
Suven Pharma Standalone September 2024 Net Sales at Rs 236.06 crore, up 5.09% Y-o-Y